Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the stocks Jim Cramer was asked about. Inquiring about the stock, a caller mentioned that they purchased it at approximately $5, and it declined to $2 before surging to around $48 on Friday and then pulling back slightly. Cramer commented: “Man, you just, you know, right now, the lottery is at $1.2 billion. You have won the lottery. You do not need to win it again. Here’s the sound. It tells you everything [kaching-kaching].” Stock market data showing ...

For more, let's bring in Amy Burroughs, the CEO of Turns Pharmaceuticals. Amy, great to have you with us. >> Thank you so much for having me back, Melissa.>> This was stunning for most investors, most analysts out there in terms of of the data. Three times better approximately than the standard of care right now. Can you can you sort of speak to what this means for patients and and how soon this drug can actually reach market.>> Yeah, absolutely. So chronic myo leukemia is a disease which is a chronic condi ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

We recently published 10 Stocks Delivering Explosive 18-190% Gains. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the last week’s heavy gainers. Terns Pharmaceuticals soared by 53 percent in just the past five trading days of the week, primarily buoyed by encouraging results from its therapy candidate for chronic myeloid leukemia (CML). In an updated report earlier in the week, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) said that its therapy candidate TERN-701 recorded a 64 percent improvement in t ...

We recently published 10 Stocks Delivering Explosive 18-190% Gains. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the last week’s heavy gainers. Terns Pharmaceuticals soared by 53 percent in just the past five trading days of the week, primarily buoyed by encouraging results from its therapy candidate for chronic myeloid leukemia (CML). In an updated report earlier in the week, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) said that its therapy candidate TERN-701 recorded a 64 percent improvement in t ...

融资事件概要 - Terns Pharmaceuticals公司于2025年12月11日完成了其先前宣布的承销公开发行 共发行了18,687,500股普通股 其中包括承销商全额行使超额配售权购买的2,437,500股 发行价格为每股40.00美元 [1] - 此次发行扣除承销折扣和佣金及其他发行费用前的总收益为7.475亿美元 所有股份均由公司发行 [1] 发行相关方 - 此次发行的联席账簿管理人为Jefferies、TD Cowen和Leerink Partners [2] - 此次发行的联席经理为Mizuho、Citizens Capital Markets和Oppenheimer & Co [2] 募集资金用途 - 公司计划将此次发行的净收益用于资助关键候选产品（包括TERN-701）的研究、临床试验、开发和制造 为TERN-701未来潜在的商业上市进行初步准备活动 以及用作营运资金和一般公司用途 [3] - 此次公开发行依据的是于2025年12月9日向美国证券交易委员会提交并于当日自动生效的S-3表格上的储架注册声明 [3] 公司业务介绍 - Terns Pharmaceuticals是一家临床阶段的肿瘤学公司 致力于通过重新构想已知生物学来提供高影响力的药物 [5] - 公司的领先项目TERN-701是一种高选择性、变构的BCR-ABL抑制剂 具有潜在的同类最佳疾病治疗特征 可能显著改善现有慢性髓性白血病治疗方法的疗效、安全性和便利性 [5]

公司融资活动 - Terns Pharmaceuticals 宣布对其增发后的承销公开发行进行定价 发行16,250,000股普通股 每股公开发行价格为40.00美元[1] - 此次发行预计在扣除承销折扣和佣金及其他费用前 总收益为6.5亿美元[1] - 公司授予承销商一项30天期权 可额外购买最多2,437,500股普通股[1] - 此次发行预计于2025年12月11日结束 取决于惯例成交条件[1] 发行承销商 - 此次发行的联席账簿管理人为Jefferies、TD Cowen和Leerink Partners[2] - 联席经理为Mizuho、Citizens Capital Markets和Oppenheimer & Co.[2] 募集资金用途 - 公司计划将此次发行的净收益用于资助关键候选产品的研究、临床试验、开发和制造 包括TERN-701[3] - 资金还将用于为TERN-701潜在未来商业发布做准备的初始活动 以及用于营运资金和一般公司用途[3] 公司业务与产品 - Terns Pharmaceuticals 是一家临床阶段肿瘤学公司[6] - 其主要项目TERN-701是一种高选择性、变构的BCR-ABL抑制剂 具有潜在的最佳疾病谱 可能显著改善现有CML（慢性髓性白血病）治疗方法的疗效、安全性和便利性[6]

文章核心观点 - 文章为作者Edmund Ingham对其付费投资通讯服务Haggerston BioHealth的推广 该服务旨在帮助投资者追踪生物技术、制药和医疗保健行业的股票动态、关键趋势和估值催化剂 [1] 作者及服务介绍 - 作者Edmund Ingham是一位生物技术顾问 拥有超过5年覆盖生物技术、医疗保健和制药行业的经验 并已汇编了超过1,000家公司的详细报告 [1] - 其领导的投资团体Haggerston BioHealth面向新手和经验丰富的生物技术投资者 [1] - 该服务提供的内容包括：需要关注的市场催化剂、买入和卖出评级、所有大型制药公司的产品销售和预测、预测数据、综合财务报表、贴现现金流分析以及按市场进行的分析 [1]

文章核心观点 - 文章是一篇推广订阅投资通讯的广告 旨在吸引对生物技术、制药和医疗保健行业股票动态感兴趣的投资者 订阅服务提供行业趋势分析、估值催化剂、公司报告以及投资评级等内容 [1] 作者与投资服务介绍 - 作者Edmund Ingham是一位生物技术顾问 拥有超过5年覆盖生物技术、医疗保健和制药行业的经验 并已汇编了超过1,000家公司的详细报告 [1] - 作者领导名为Haggerston BioHealth的投资团体 该团体面向生物技术投资的新手和经验丰富的投资者 [1] - 该投资团体提供的服务包括：提示值得关注的市场催化剂、提供买入和卖出评级、提供所有大型制药公司的产品销售数据和预测、预测、综合财务报表、贴现现金流分析以及按市场细分进行的分析 [1]

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the best performers on Monday. Terns soared to a new all-time high on Monday as investors took heart from the encouraging results of its clinical trial to test the efficacy of drug candidate, TERN-701, in patients with previously treated chronic myeloid leukemia (CML). At intra-day trading, the stock climbed to its highest price of $45 before trimming gains to finish the ...